Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.02, Zacks reports. The firm had revenue of $30.54 million for the quarter, compared to analysts' expectations of $30.29 million. Karyopharm Therapeutics updated its FY 2025 guidance to EPS.
Karyopharm Therapeutics Stock Down 1.9 %
Shares of Karyopharm Therapeutics stock traded down $0.01 on Friday, hitting $0.60. 1,057,547 shares of the company traded hands, compared to its average volume of 787,132. The company has a 50-day moving average price of $0.66 and a 200 day moving average price of $0.76. Karyopharm Therapeutics has a 12-month low of $0.53 and a 12-month high of $1.70. The company has a market cap of $75.54 million, a PE ratio of -0.59 and a beta of 0.06.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday. StockNews.com cut shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 22nd. Royal Bank of Canada restated an "outperform" rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a report on Thursday. Finally, Piper Sandler boosted their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $5.00.
Check Out Our Latest Report on KPTI
About Karyopharm Therapeutics
(
Get Free Report)
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Featured Articles
Before you consider Karyopharm Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Karyopharm Therapeutics wasn't on the list.
While Karyopharm Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
